{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:25:20Z","timestamp":1775121920628,"version":"3.50.1"},"reference-count":211,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jval.2019.06.011","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T17:26:41Z","timestamp":1568136401000},"page":"1329-1344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions"],"prefix":"10.1016","volume":"22","author":[{"given":"Tinevimbo","family":"Shiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Keaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geetanjali","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel D.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2019.06.011_bib1","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/infdis\/jis240","article-title":"Aging population and future burden of pneumococcal pneumonia in the United States","volume":"205","author":"Wroe","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1469-0691.2010.03190.x","article-title":"Streptococcus pneumoniae: still a major pathogen","volume":"16","author":"Varon","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jval.2019.06.011_bib3","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1016\/j.vaccine.2010.05.030","article-title":"Clinical and economic burden of pneumococcal disease in older US adults","volume":"28","author":"Weycker","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1473-3099(04)00938-7","article-title":"Streptococcus pneumoniae colonisation: the key to pneumococcal disease","volume":"4","author":"Bogaert","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1183\/09059180.00008911","article-title":"The remaining challenges of pneumococcal disease in adults","volume":"21","author":"Ludwig","year":"2012","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jval.2019.06.011_bib6","doi-asserted-by":"crossref","first-page":"a010215","DOI":"10.1101\/cshperspect.a010215","article-title":"The Pneumococcus: epidemiology, microbiology, and pathogenesis","volume":"3","author":"Henriques-Normark","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jval.2019.06.011_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1542\/peds.106.2.367","article-title":"Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis","volume":"106","author":"Overturf","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.jval.2019.06.011_bib8","unstructured":"CDC. Pneumococcal vaccination: what everyone should know. Centers for Disease Control and Prevention. Accessed November 20,\u00a02017."},{"key":"10.1016\/j.jval.2019.06.011_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41479-017-0030-5","article-title":"Pneumococcal conjugate vaccine implementation in middle-income countries","volume":"9","author":"Tricarico","year":"2017","journal-title":"Pneumonia (Nathan)"},{"key":"10.1016\/j.jval.2019.06.011_bib10","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1086\/503805","article-title":"Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease","volume":"193","author":"Hammitt","year":"2006","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3201\/eid1605.091223","article-title":"Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands","volume":"16","author":"Rodenburg","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib12","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2009.06.091","article-title":"National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential","volume":"27","author":"Hsieh","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib13","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ijporl.2005.03.013","article-title":"Health-related quality of life in children with otitis media","volume":"69","author":"Brouwer","year":"2005","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.jval.2019.06.011_bib14","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/CCM.0b013e3181d8cc1d","article-title":"Long-term mortality and quality of life in sepsis: a systematic review","volume":"38","author":"Winters","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jval.2019.06.011_bib15","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1016\/j.vaccine.2018.03.070","article-title":"Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older","volume":"36","author":"Nishikawa","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib16","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1016\/j.vaccine.2009.05.061","article-title":"Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions","volume":"27","author":"Ogilvie","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib17","first-page":"47","article-title":"Economic evaluations of adult pneumococcal vaccination strategies","volume":"1","author":"Beutels","year":"2001","journal-title":"Expert Rev"},{"issue":"4","key":"10.1016\/j.jval.2019.06.011_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1586\/14760584.2.4.477","article-title":"Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands","volume":"2","author":"Postma","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jval.2019.06.011_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40273-013-0113-y","article-title":"Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies","volume":"32","author":"van de Vooren","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2019.06.011_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14760584.2017.1242419","article-title":"Evaluating the costs and benefits of pneumococcal vaccination in adults","volume":"16","author":"Porchia","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jval.2019.06.011_bib21","first-page":"1","article-title":"Cost effectiveness of pneumococcal vaccination in children in low- and middle-income countries: a systematic review","author":"Saokaew","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2019.06.011_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1332\/174426410X482999","article-title":"A\u00a0web-based tool for adjusting costs to a specific target currency and price year","volume":"6","author":"Ian","year":"2010","journal-title":"Evidence Policy"},{"key":"10.1016\/j.jval.2019.06.011_bib23","doi-asserted-by":"crossref","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2019.06.011_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2431-13-122","article-title":"Variation of health-related quality of life assessed by caregivers and patients affected by severe childhood infections","volume":"13","author":"Kulpeng","year":"2013","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.jval.2019.06.011_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/0272989X08327398","article-title":"Estimating preference-based health utilities index mark 3 utility scores for childhood conditions in England and Scotland","volume":"29","author":"Petrou","year":"2009","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2019.06.011_bib26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1651-2227.2008.01136.x","article-title":"Health related quality of life in survivors of pneumococcal meningitis","volume":"98","author":"Legood","year":"2009","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jval.2019.06.011_bib27","first-page":"43","article-title":"Parents' utilities for outcomes of occult bacteremia","volume":"154","author":"Bennett","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"12","key":"10.1016\/j.jval.2019.06.011_bib28","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/hec.3259","article-title":"Measuring health spillovers for economic evaluation: a case study in meningitis","volume":"25","author":"Al-Janabi","year":"2016","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2019.06.011_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1542\/peds.113.2.283","article-title":"Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine","volume":"113","author":"Prosser","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.jval.2019.06.011_bib30","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jval.2011.05.007","article-title":"Estimation and comparison of EQ-5D health states' utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom","volume":"14","author":"Galante","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2019.06.011_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpeds.2009.01.040","article-title":"Improving decision analyses: parent preferences (utility values) for pediatric health outcomes","volume":"155","author":"Carroll","year":"2009","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jval.2019.06.011_bib32","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/archinte.1996.00440130115012","article-title":"Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia","volume":"156","author":"Coley","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jval.2019.06.011_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1086\/313601","article-title":"Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps","volume":"30","author":"Vold Pepper","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib34","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.1997.03550160053038","article-title":"Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people","volume":"278","author":"Sisk","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2019.06.011_bib35","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1001\/jama.1990.03450220076026","article-title":"Pneumococcal vaccine. Efficacy and associated cost savings","volume":"264","author":"Gable","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2019.06.011_bib36","first-page":"79","article-title":"Cost-effectiveness of pneumococcal vaccine: implications for managed care","volume":"5","author":"Holzer","year":"1993","journal-title":"J\u00a0Re Pharm Econ"},{"key":"10.1016\/j.jval.2019.06.011_bib37","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.clinthera.2010.07.019","article-title":"Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the United States during an influenza pandemic","volume":"32","author":"Dhankhar","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2019.06.011_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amepre.2012.11.035","article-title":"Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults","volume":"44","author":"Smith","year":"2013","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jval.2019.06.011_bib39","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1016\/j.vaccine.2013.06.037","article-title":"Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults","volume":"31","author":"Smith","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2012.169","article-title":"Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine","volume":"307","author":"Smith","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2019.06.011_bib41","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJM198009043031004","article-title":"Cost effectiveness of vaccination against pneumococcal pneumonia","volume":"303","author":"Willems","year":"1980","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2019.06.011_bib42","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1016\/j.vaccine.2009.03.059","article-title":"Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: a cost-effectiveness analysis","volume":"27","author":"Smith","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib43","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.vaccine.2008.01.007","article-title":"Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis","volume":"26","author":"Smith","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib44","first-page":"200","article-title":"Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic","volume":"16","author":"Smith","year":"2010","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2019.06.011_bib45","doi-asserted-by":"crossref","first-page":"960","DOI":"10.7326\/0003-4819-138-12-200306170-00007","article-title":"Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race","volume":"138","author":"Sisk","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2019.06.011_bib46","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1177\/027298902237705","article-title":"Cost-effectiveness of the pneumococcal vaccine in healthy younger adults","volume":"22","author":"Pepper","year":"2002","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2019.06.011_bib47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ije\/dyh341","article-title":"An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting","volume":"34","author":"Mangtani","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jval.2019.06.011_bib48","doi-asserted-by":"crossref","first-page":"e0149540","DOI":"10.1371\/journal.pone.0149540","article-title":"Cost-effectiveness of vaccinating immunocompetent >65 year olds with the 13-valent pneumococcal conjugate vaccine in England","volume":"11","author":"van Hoek","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2019.06.011_bib49","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/qjmed\/hcl042","article-title":"The economic cost of invasive pneumococcal disease and the potential for reduction by vaccination in an adult population in South Yorkshire","volume":"99","author":"Parsons","year":"2006","journal-title":"QJM"},{"key":"10.1016\/j.jval.2019.06.011_bib50","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1023\/B:EJEP.0000024752.48929.bd","article-title":"The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales","volume":"19","author":"Melegaro","year":"2004","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jval.2019.06.011_bib51","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/jech.2008.081885","article-title":"Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities","volume":"63","author":"You","year":"2009","journal-title":"J\u00a0Epidemiol Community Health"},{"key":"10.1016\/j.jval.2019.06.011_bib52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00019053-200017060-00005","article-title":"Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium","volume":"17","author":"De Graeve","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2019.06.011_bib53","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.vaccine.2016.03.003","article-title":"The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: an exploration of influential factors for Belgium","volume":"34","author":"Blommaert","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib54","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00019053-200119020-00008","article-title":"Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands","volume":"19","author":"Postma","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2019.06.011_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/eurpub\/7.2.153","article-title":"Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands","volume":"7","author":"Baltussen","year":"1997","journal-title":"Eur J Public Health"},{"issue":"5","key":"10.1016\/j.jval.2019.06.011_bib56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1586\/erp.12.54","article-title":"Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany (provisional abstract)","volume":"12","author":"Jiang","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2019.06.011_bib57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2191-1991-2-4","article-title":"Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany","volume":"2","author":"Kuhlmann","year":"2012","journal-title":"Health Econ Rev"},{"key":"10.1016\/j.jval.2019.06.011_bib58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10096-007-0327-z","article-title":"Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries","volume":"26","author":"Evers","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib59","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1086\/313977","article-title":"Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries","volume":"31","author":"Ament","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib60","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF03404802","article-title":"A\u00a0cost-effectiveness analysis of pneumococcal vaccination in street-involved, HIV-infected patients","volume":"91","author":"Marra","year":"2000","journal-title":"Can J Public Health"},{"key":"10.1016\/j.jval.2019.06.011_bib61","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.vaccine.2006.08.005","article-title":"Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy","volume":"25","author":"Merito","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib62","first-page":"1037","article-title":"Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in Sao Paulo State, Brazil","volume":"7","author":"Neto","year":"2011","journal-title":"Hum"},{"key":"10.1016\/j.jval.2019.06.011_bib63","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0399-077X(02)00393-1","article-title":"Cost effectiveness analysis of pneumococcal vaccination of older people in France","volume":"32","author":"Amazian","year":"2002","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.jval.2019.06.011_bib64","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4161\/hv.21571","article-title":"Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland","volume":"8","author":"Grzesiowski","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jval.2019.06.011_bib65","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1016\/j.vaccine.2011.08.006","article-title":"Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population","volume":"29","author":"Castaneda-Orjuela","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jval.2019.06.011_bib66","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4161\/hv.7.4.14188","article-title":"Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey","volume":"7","author":"Akin","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.jval.2019.06.011_bib67","first-page":"193","article-title":"Cost-effectiveness analysis of pneumococcal vaccination in the elderly Spanish population","volume":"10","author":"Jimenez","year":"1996","journal-title":"Br J Med Econ"},{"key":"10.1016\/j.jval.2019.06.011_bib68","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-2334-13-175","article-title":"Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model","volume":"13","author":"Pradas","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib69","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1471-2334-14-172","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia","volume":"14","author":"Ordonez","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib70","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jep.12131","article-title":"Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults >50 years with underlying chronic medical conditions","volume":"20","author":"Martikainen","year":"2014","journal-title":"J\u00a0Eval Clin Pract"},{"key":"10.1016\/j.jval.2019.06.011_bib71","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","article-title":"Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands","volume":"46","author":"Mangen","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jval.2019.06.011_bib72","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4161\/hv.23268","article-title":"Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy","volume":"9","author":"Boccalini","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jval.2019.06.011_bib73","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.vaccine.2004.08.051","article-title":"Pneumococcal pneumonia in the UK\u2014how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV)","volume":"23","author":"McIntosh","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib74","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12325-014-0115-y","article-title":"Cost-effectiveness of pneumococcal vaccines for adults in the United States","volume":"31","author":"Chen","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.jval.2019.06.011_bib75","doi-asserted-by":"crossref","first-page":"7620","DOI":"10.1016\/j.vaccine.2010.09.053","article-title":"Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds","volume":"28","author":"Smith","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib76","doi-asserted-by":"crossref","first-page":"e0139140","DOI":"10.1371\/journal.pone.0139140","article-title":"Economic evaluation of immunisation programme of 23-valent pneumococcal polysaccharide vaccine and the inclusion of 13-valent pneumococcal conjugate vaccine in the list for single-dose subsidy to the elderly in Japan","volume":"10","author":"Hoshi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2019.06.011_bib77","doi-asserted-by":"crossref","first-page":"e0130217","DOI":"10.1371\/journal.pone.0130217","article-title":"Cost-effectiveness analysis of universal vaccination of adults aged 60 years with 23-valent pneumococcal polysaccharide vaccine versus current practice in Brazil","volume":"10","author":"de Soarez","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2019.06.011_bib78","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1016\/j.vaccine.2013.10.024","article-title":"Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions","volume":"31","author":"Cho","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib79","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1080\/21645515.2015.1011957","article-title":"A\u00a0comparative public health and budget impact analysis of pneumococcal vaccines: the French case","volume":"11","author":"Jiang","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jval.2019.06.011_bib80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40261-015-0345-z","article-title":"Cost effectiveness of the 13-valent pneumococcal conjugate vaccination program in chronic obstructive pulmonary disease patients aged 50+ years in Spain","volume":"36","author":"Rodriguez Gonzalez-Moro","year":"2016","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jval.2019.06.011_bib81","first-page":"913","article-title":"Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK","volume":"14","author":"Jiang","year":"2014","journal-title":"Expert Rev"},{"key":"10.1016\/j.jval.2019.06.011_bib82","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1097\/INF.0000000000001288","article-title":"Cost-effectiveness and health benefits of pediatric 23-valent pneumococcal polysaccharide vaccine, 7-valent pneumococcal conjugate vaccine and forecasting 13-valent pneumococcal conjugate vaccine in China","volume":"35","author":"Mo","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jval.2019.06.011_bib83","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jfma.2011.10.006","article-title":"Economic evaluation of universal 7-valent pneumococcal conjugate vaccination in Taiwan: a cost-effectiveness analysis","volume":"112","author":"Wu","year":"2013","journal-title":"J\u00a0Formos Med Assoc"},{"key":"10.1016\/j.jval.2019.06.011_bib84","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/00365540500321512","article-title":"Economic evaluation of pneumococcal conjugate vaccination in Finland","volume":"37","author":"Salo","year":"2005","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib85","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)60195-0","article-title":"Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis","volume":"369","author":"Sinha","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2019.06.011_bib86","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1016\/j.vaccine.2011.06.091","article-title":"Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines","volume":"29","author":"Tyo","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib87","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1016\/j.vaccine.2009.09.057","article-title":"Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada","volume":"27","author":"Poirier","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib88","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1016\/S0264-410X(03)00361-X","article-title":"Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada","volume":"21","author":"Wals","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib89","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10198-006-0013-6","article-title":"Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects","volume":"9","author":"Lloyd","year":"2008","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2019.06.011_bib90","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.provac.2009.07.012","article-title":"Simulation model for comparing the costs and effectiveness of different pneumococcal conjugate vaccines","volume":"1","author":"Wals","year":"2009","journal-title":"Procedia Vaccinol"},{"issue":"1","key":"10.1016\/j.jval.2019.06.011_bib91","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.provac.2009.07.012","article-title":"Simulation model for comparing the costs and effectiveness of different pneumococcal conjugate vaccines","volume":"1","author":"De Wals","year":"2009","journal-title":"Procedia Vaccinol"},{"key":"10.1016\/j.jval.2019.06.011_bib92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1478-7547-11-21","article-title":"A\u00a0cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries","volume":"11","author":"Marti","year":"2013","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.jval.2019.06.011_bib93","doi-asserted-by":"crossref","first-page":"e67324","DOI":"10.1371\/journal.pone.0067324","article-title":"Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children","volume":"8","author":"Ayieko","year":"2013","journal-title":"PLoS One"},{"issue":"suppl 1","key":"10.1016\/j.jval.2019.06.011_bib94","doi-asserted-by":"crossref","first-page":"A209","DOI":"10.1016\/j.vaccine.2014.12.043","article-title":"Cost-effectiveness of pneumococcal conjugate vaccination in Croatia","volume":"33","author":"Vucina","year":"2015","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.jval.2019.06.011_bib95","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1016\/j.vaccine.2011.04.111","article-title":"Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina","volume":"29","author":"Uruena","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib96","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.inhe.2011.08.003","article-title":"Cost effectiveness of child pneumococcal conjugate vaccination in GAVI-eligible countries","volume":"3","author":"Tasslimi","year":"2011","journal-title":"Int Health"},{"key":"10.1016\/j.jval.2019.06.011_bib97","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.inhe.2011.08.004","article-title":"Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries","volume":"3","author":"Nakamura","year":"2011","journal-title":"Int Health"},{"key":"10.1016\/j.jval.2019.06.011_bib98","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.vhri.2014.04.008","article-title":"Economic impact of pneumococcal protein-D conjugate vaccine (PHiD-CV) on the Malaysian National Immunization Programme","volume":"3","author":"Aljunid","year":"2014","journal-title":"Value Health Reg Issues"},{"issue":"suppl 1","key":"10.1016\/j.jval.2019.06.011_bib99","doi-asserted-by":"crossref","first-page":"A143","DOI":"10.1016\/j.vaccine.2014.12.078","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay","volume":"33","author":"Kieninger","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib100","first-page":"388","article-title":"Post-introduction economic evaluation of pneumococcal conjugate vaccination in Ecuador, Honduras, and Paraguay","volume":"38","author":"Constenla","year":"2015","journal-title":"Rev Panam Salud Publica"},{"issue":"suppl 1","key":"10.1016\/j.jval.2019.06.011_bib101","doi-asserted-by":"crossref","first-page":"A154","DOI":"10.1016\/j.vaccine.2014.12.039","article-title":"Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru","volume":"33","author":"Mezones-Holguin","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib102","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1186\/1471-2458-13-1025","article-title":"Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru","volume":"13","author":"Gomez","year":"2013","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jval.2019.06.011_bib103","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jval.2013.03.1632","article-title":"Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in Turkey","volume":"16","author":"Turel","year":"2013","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2019.06.011_bib104","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1590\/S1020-49892009001200007","article-title":"Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil","volume":"26","author":"Vespa","year":"2009","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.jval.2019.06.011_bib105","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1016\/j.vaccine.2013.03.047","article-title":"Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?","volume":"31","author":"Kulpeng","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib106","doi-asserted-by":"crossref","first-page":"e0131156","DOI":"10.1371\/journal.pone.0131156","article-title":"Do pneumococcal conjugate vaccines represent good value for money in a lower-middle income country? A cost-utility analysis in the Philippines","volume":"10","author":"Haasis","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2019.06.011_bib107","doi-asserted-by":"crossref","first-page":"e6879","DOI":"10.1136\/bmj.e6879","article-title":"Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis","volume":"345","author":"Rozenbaum","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2019.06.011_bib108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12962-015-0032-1","article-title":"Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia","volume":"13","author":"Ordonez","year":"2015","journal-title":"Cost Eff Resour Alloc"},{"issue":"1 suppl","key":"10.1016\/j.jval.2019.06.011_bib109","first-page":"S15","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach","volume":"15","author":"Wu","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2019.06.011_bib110","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1016\/j.vaccine.2013.03.052","article-title":"Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan","volume":"31","author":"Hoshi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib111","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1016\/j.vaccine.2012.10.017","article-title":"The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England","volume":"30","author":"van Hoek","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib112","doi-asserted-by":"crossref","first-page":"8077","DOI":"10.1016\/j.vaccine.2011.08.050","article-title":"The potential cost-effectiveness of infant pneumococcal vaccines in Australia","volume":"29","author":"Newall","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib113","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.vaccine.2012.04.028","article-title":"Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland","volume":"30","author":"Blank","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib114","first-page":"54","article-title":"Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands","volume":"64","author":"Strutton","year":"2012","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.jval.2019.06.011_bib115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2334-12-101","article-title":"Cost-effectiveness of 2\u00a0+ 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada","volume":"12","author":"Earnshaw","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib116","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1016\/j.vaccine.2010.05.058","article-title":"Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines","volume":"28","author":"Chuck","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib117","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clinthera.2012.12.006","article-title":"Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden","volume":"35","author":"Klok","year":"2013","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.jval.2019.06.011_bib118","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/21645515.2015.1067351","article-title":"Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong","volume":"12","author":"Wu","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jval.2019.06.011_bib119","first-page":"61","article-title":"Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise","volume":"15","author":"Knerer","year":"2012","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2019.06.011_bib120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.vhri.2013.01.012","article-title":"The health economic impact of universal infant vaccination with the 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine as compared with 13-valent pneumococcal conjugate vaccine in Hong Kong","volume":"2","author":"Lee","year":"2013","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jval.2019.06.011_bib121","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1472-6963-12-386","article-title":"Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model","volume":"12","author":"Bakir","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jval.2019.06.011_bib122","doi-asserted-by":"crossref","first-page":"8564","DOI":"10.1016\/j.vaccine.2011.09.025","article-title":"Economic evaluation of second generation pneumococcal conjugate vaccines in Norway","volume":"29","author":"Robberstad","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib123","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1016\/j.vaccine.2006.04.042","article-title":"Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program","volume":"24","author":"Wisloff","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib124","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1016\/j.vaccine.2009.08.045","article-title":"Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States","volume":"27","author":"Ray","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib125","first-page":"S526","article-title":"Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs","volume":"6","author":"Weycker","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2019.06.011_bib126","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.inf.0000222403.42974.8b","article-title":"Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects","volume":"25","author":"Ray","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jval.2019.06.011_bib127","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1542\/peds.2008-1482","article-title":"New vaccines against otitis media: projected benefits and cost-effectiveness","volume":"123","author":"O'Brien","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jval.2019.06.011_bib128","first-page":"28","article-title":"Assessing cost and cost effectiveness of pneumococcal disease and vaccination","volume":"3","author":"Black","year":"2003","journal-title":"Managed Care Consultant"},{"key":"10.1016\/j.jval.2019.06.011_bib129","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.283.11.1460","article-title":"Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children","volume":"283","author":"Lieu","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2019.06.011_bib130","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/S0264-410X(03)00031-8","article-title":"The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine","volume":"21","author":"McIntosh","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib131","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2004.05.003","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales","volume":"22","author":"Melegaro","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib132","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1016\/S0264-410X(03)00361-X","article-title":"Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada","volume":"21","author":"De Wals","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib133","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1086\/345833","article-title":"A\u00a0pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada","volume":"36","author":"Lebel","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib134","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1524-4733.2008.00341.x","article-title":"Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland","volume":"11","author":"Tilson","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2019.06.011_bib135","doi-asserted-by":"crossref","first-page":"32","DOI":"10.18553\/jmcp.2010.16.1.32","article-title":"Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea","volume":"16","author":"Sohn","year":"2010","journal-title":"J\u00a0Manage Care Pharm"},{"issue":"5","key":"10.1016\/j.jval.2019.06.011_bib136","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1590\/S1020-49892008001100002","article-title":"Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis","volume":"24","author":"Sinha","year":"2008","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.jval.2019.06.011_bib137","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.vaccine.2008.12.033","article-title":"The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine","volume":"27","author":"Silfverdal","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib138","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/00365540802014872","article-title":"Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden","volume":"40","author":"Bergman","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib139","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.vaccine.2010.01.005","article-title":"Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar)","volume":"28","author":"Rozenbaum","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib140","doi-asserted-by":"crossref","first-page":"c2509","DOI":"10.1136\/bmj.c2509","article-title":"Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines","volume":"340","author":"Rozenbaum","year":"2010","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.jval.2019.06.011_bib141","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1016\/j.vaccine.2007.01.088","article-title":"Enhanced decision support for policy makers using a web interface to health-economic models\u2014Illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands","volume":"25","author":"Hubben","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib142","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/S0149-2918(03)80322-3","article-title":"Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands","volume":"25","author":"Bos","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2019.06.011_bib143","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12879-015-1021-x","article-title":"The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China","volume":"15","author":"Caldwell","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib144","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.vhri.2014.04.007","article-title":"Estimating the cost-effectiveness of the 7-valent pneumococcal conjugate vaccine in Shanghai, China","volume":"3","author":"Hu","year":"2014","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jval.2019.06.011_bib145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1472-6963-14-56","article-title":"Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination","volume":"14","author":"Che","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jval.2019.06.011_bib146","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1524-4733.2004.71263.x","article-title":"A\u00a0pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain","volume":"7","author":"Asensi","year":"2004","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2019.06.011_bib147","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.vaccine.2005.01.018","article-title":"Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain)","volume":"23","author":"Navas","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib148","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.vaccine.2015.11.053","article-title":"Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: uncertain herd impact on pneumonia critical","volume":"34","author":"Newall","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib149","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.vaccine.2003.09.036","article-title":"The cost-effectiveness of pneumococcal conjugate vaccination in Australia","volume":"22","author":"Butler","year":"2004","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jval.2019.06.011_bib150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10198-008-0098-1","article-title":"Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects","volume":"10","author":"Claes","year":"2009","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2019.06.011_bib151","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00019053-200321080-00005","article-title":"Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany","volume":"21","author":"Claes","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2019.06.011_bib152","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/j.vaccine.2012.02.033","article-title":"Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan","volume":"30","author":"Hoshi","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib153","doi-asserted-by":"crossref","first-page":"315","DOI":"10.25100\/cm.v41i4.722","article-title":"Cost effectiveness of heptavalent pneumococcal conjugate vaccine in populations of high risk in Colombia","volume":"41","author":"Guzman","year":"2010","journal-title":"Colombia Medica"},{"key":"10.1016\/j.jval.2019.06.011_bib154","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1016\/S0264-410X(03)00193-2","article-title":"Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland","volume":"21","author":"Ess","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib155","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.vaccine.2009.12.070","article-title":"Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina","volume":"28","author":"Giglio","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib156","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.healthpol.2008.05.016","article-title":"Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy","volume":"89","author":"Giorgi-Rossi","year":"2009","journal-title":"Health Policy"},{"key":"10.1016\/j.jval.2019.06.011_bib157","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1471-2334-10-260","article-title":"Economic evaluation of pneumococcal conjugate vaccination in The Gambia","volume":"10","author":"Kim","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"suppl 3","key":"10.1016\/j.jval.2019.06.011_bib158","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1111\/j.1524-4733.2009.00626.x","article-title":"Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong","volume":"12","author":"Lee","year":"2009","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2019.06.011_bib159","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1590\/S1020-49892008000800004","article-title":"Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay","volume":"24","author":"Constenla","year":"2008","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.jval.2019.06.011_bib160","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1471-2334-11-248","article-title":"Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia","volume":"11","author":"Aljunid","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib161","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1759-8893.2011.00057.x","article-title":"The cost effectiveness of pneumococcal conjugate vaccine in the routine infant immunisation programme of The Gambia","volume":"2","author":"Touray","year":"2011","journal-title":"J\u00a0Pharm Health Services Res"},{"key":"10.1016\/j.jval.2019.06.011_bib162","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.vaccine.2012.01.031","article-title":"Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children","volume":"30","author":"Castaneda-Orjuela","year":"2012","journal-title":"Vaccine"},{"issue":"suppl 1","key":"10.1016\/j.jval.2019.06.011_bib163","doi-asserted-by":"crossref","first-page":"A219","DOI":"10.1016\/j.vaccine.2014.12.070","article-title":"Cost-effectiveness of pneumococcal conjugate vaccination in Georgia","volume":"33","author":"Komakhidze","year":"2015","journal-title":"Vaccine"},{"issue":"suppl 1","key":"10.1016\/j.jval.2019.06.011_bib164","doi-asserted-by":"crossref","first-page":"A182","DOI":"10.1016\/j.vaccine.2014.12.044","article-title":"Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013","volume":"33","author":"Sibak","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib165","doi-asserted-by":"crossref","first-page":"9640","DOI":"10.1016\/j.vaccine.2011.10.038","article-title":"Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain)","volume":"29","author":"Diez-Domingo","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jval.2019.06.011_bib166","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3855\/jidc.5855","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children","volume":"8","author":"Mezones-Holguin","year":"2014","journal-title":"J\u00a0Infect Dev Ctries"},{"key":"10.1016\/j.jval.2019.06.011_bib167","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/1471-2334-13-229","article-title":"Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States","volume":"13","author":"McGarry","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jval.2019.06.011_bib168","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.4161\/hv.29008","article-title":"A\u00a0few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children","volume":"10","author":"Vemer","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jval.2019.06.011_bib169","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clinthera.2011.12.007","article-title":"Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model","volume":"34","author":"By","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2019.06.011_bib170","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.vhri.2014.04.004","article-title":"Cost-effectiveness analysis of pneumococcal vaccination with the pneumococcal polysaccharide NTHi protein D conjugate vaccine in the Philippines","volume":"3","author":"Zhang","year":"2014","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jval.2019.06.011_bib171","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1016\/j.vaccine.2011.10.013","article-title":"Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy","volume":"29","author":"Boccalini","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2019.06.011_bib172","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1542\/peds.2012-3350","article-title":"Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine","volume":"132","author":"Stoecker","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jval.2019.06.011_bib173","first-page":"901","article-title":"A\u00a0public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK","volume":"14","author":"Jiang","year":"2014","journal-title":"Expert Rev"},{"key":"10.1016\/j.jval.2019.06.011_bib174","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00019048-199806000-00006","article-title":"Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia","volume":"7","author":"Richerson","year":"1998","journal-title":"Infect Dis Clin Pract (Baltim Md)"},{"key":"10.1016\/j.jval.2019.06.011_bib175","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1185\/03007990903102743","article-title":"Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US","volume":"25","author":"Raut","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2019.06.011_bib176","first-page":"381","article-title":"An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia","volume":"6","author":"Rittenhouse","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2019.06.011_bib177","first-page":"348","article-title":"Cost-effectiveness in the hospital use of antibiotics: introductory considerations","volume":"5","author":"Capri","year":"1993","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.jval.2019.06.011_bib178","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF02560518","article-title":"Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany","volume":"27","author":"Dietrich","year":"1999","journal-title":"Infection"},{"key":"10.1016\/j.jval.2019.06.011_bib179","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1185\/030079908X273336","article-title":"A\u00a0cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium","volume":"24","author":"Martin","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2019.06.011_bib180","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dkm033","article-title":"Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance","volume":"59","author":"Martin","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jval.2019.06.011_bib181","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1592\/phco.20.5.461.35052","article-title":"Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia","volume":"20","author":"Najib","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jval.2019.06.011_bib182","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1378\/chest.119.5.1439","article-title":"Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia","volume":"119","author":"Dresser","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jval.2019.06.011_bib183","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11096-004-7039-6","article-title":"A\u00a0clinical and economic study of community-acquired pneumonia between single versus combination therapy","volume":"27","author":"Hasali","year":"2005","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.jval.2019.06.011_bib184","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10198-011-0296-0","article-title":"Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin\/tazobactam","volume":"13","author":"Edwards","year":"2012","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2019.06.011_bib185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12911-016-0270-y","article-title":"Cost effectiveness of adherence to IDSA\/ATS guidelines in elderly patients hospitalized for community-aquired pneumonia","volume":"16","author":"Egger","year":"2016","journal-title":"BMC Med Inf Decis Mak"},{"key":"10.1016\/j.jval.2019.06.011_bib186","first-page":"195","article-title":"Modelling the use of three antibiotics in the management of community-acquired pneumonia","volume":"8","author":"Backhouse","year":"1995","journal-title":"Br J Med Econ"},{"key":"10.1016\/j.jval.2019.06.011_bib187","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1378\/chest.122.4.1271","article-title":"Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia","volume":"122","author":"Paladino","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jval.2019.06.011_bib188","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12887-015-0510-9","article-title":"A\u00a0randomized controlled trial of hospital versus home based therapy with oral amoxicillin for severe pneumonia in children aged 3 - 59 months: The IndiaCLEN Severe Pneumonia Oral Therapy (ISPOT) Study","volume":"15","author":"Patel","year":"2015","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.jval.2019.06.011_bib189","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diagmicrobio.2007.07.006","article-title":"Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with\/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia","volume":"60","author":"Bhavnani","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"15","key":"10.1016\/j.jval.2019.06.011_bib190","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/ajhp\/56.15.1521","article-title":"Azithromycin versus erythromycin for community-acquired pneumonia: a cost-minimization analysis","volume":"56","author":"Howard","year":"1999","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jval.2019.06.011_bib191","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00019048-199812000-00007","article-title":"Continuous vs. intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia","volume":"7","author":"Ambrose","year":"1998","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.jval.2019.06.011_bib192","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1524-4733.2006.00105.x","article-title":"An economic evaluation of two ototopical treatments for acute otitis media in tympanostomy tube patients","volume":"9","author":"Roland","year":"2006","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2019.06.011_bib193","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1093\/pch\/15.7.e14","article-title":"Treatment cost effectiveness in acute otitis media: a watch-and-wait approach versus amoxicillin","volume":"15","author":"Gaboury","year":"2010","journal-title":"Paediatr Child Health"},{"key":"10.1016\/j.jval.2019.06.011_bib194","first-page":"371","article-title":"Recurrent otitis media: a cost-utility analysis of simulated treatment using tympanostomy tubes vs antibiotic prophylaxis","volume":"11","author":"Bisonni","year":"1991","journal-title":"Fam Pract Res J"},{"key":"10.1016\/j.jval.2019.06.011_bib195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1370\/afm.626","article-title":"Cost-effectiveness analysis of treatment options for acute otitis media","volume":"5","author":"Coco","year":"2007","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.jval.2019.06.011_bib196","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/archotol.127.12.1471","article-title":"Economic evaluation of ventilation tubes in otitis media with effusion","volume":"127","author":"Hartman","year":"2001","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jval.2019.06.011_bib197","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1017\/S0266462306051373","article-title":"Cost-effectiveness of implementing national guidelines in the treatment of acute otitis media in children","volume":"22","author":"Koskinen","year":"2006","journal-title":"Int J Technol Assess Health Care"},{"issue":"10","key":"10.1016\/j.jval.2019.06.011_bib198","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1525-1497.2001.00429.x","article-title":"Strategies for diagnosing and treating suspected acute bacterial sinusitis: a cost-effectiveness analysis","volume":"16","author":"Balk","year":"2001","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jval.2019.06.011_bib199","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1542\/peds.2007-1886","article-title":"Cost-effectiveness of competing strategies for the treatment of pediatric empyema","volume":"121","author":"Cohen","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.jval.2019.06.011_bib200","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/archinte.161.1.111","article-title":"Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines","volume":"161","author":"Weaver","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jval.2019.06.011_bib201","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2967\/jnumed.111.089714","article-title":"Cost-effectiveness of routine (18)F-FDG PET\/CT in high-risk patients with gram-positive bacteremia","volume":"52","author":"Vos","year":"2011","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jval.2019.06.011_bib202","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s11606-013-2400-x","article-title":"Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia","volume":"28","author":"Smith","year":"2013","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jval.2019.06.011_bib203","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1017\/S0266462303000667","article-title":"Application of a diagnostic decision rule in children with meningeal signs: a cost-minimization study","volume":"19","author":"Oostenbrink","year":"2003","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jval.2019.06.011_bib204","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0149-2918(00)88483-0","article-title":"Pharmaceutical economics & health policy. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin","volume":"22","author":"Palmer","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2019.06.011_bib205","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jval.2012.11.009","article-title":"Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis","volume":"16","author":"Michaelidis","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2019.06.011_bib206","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1086\/587155","article-title":"Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients","volume":"29","author":"Middleton","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jval.2019.06.011_bib207","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0749-3797(01)00312-9","article-title":"Cost utility of public clinics to increase pneumococcal vaccines in the elderly","volume":"21","author":"Mukamel","year":"2001","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.1016\/j.jval.2019.06.011_bib208","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1183\/09031936.00052506","article-title":"Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia","volume":"29","author":"Menendez","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jval.2019.06.011_bib209","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jpeds.2015.09.025","article-title":"A\u00a0cost-effectiveness analysis of obtaining blood cultures in children hospitalized for community-acquired pneumonia","volume":"167","author":"Andrews","year":"2015","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jval.2019.06.011_bib210","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1177\/027298902237711","article-title":"Cost-benefit analysis of a new HEDIS performance measure for pneumococcal vaccination","volume":"22","author":"Ahmed","year":"2002","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2019.06.011_bib211","doi-asserted-by":"crossref","first-page":"e0140202","DOI":"10.1371\/journal.pone.0140202","article-title":"Impact of an educational program to reduce healthcare resources in community-acquired pneumonia: the EDUCAP randomized controlled trial","volume":"10","author":"Adamuz","year":"2015","journal-title":"PLoS One"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519323010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519323010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:16:49Z","timestamp":1761095809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301519323010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":211,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1098301519323010"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2019.06.011","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2019.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}